Resverlogix Honored by World Economic Forum with 2008 Award

    CALGARY, Jan. 24 /CNW/ -

    WHAT:        World Economic Forum Technology Pioneer Award Winner

    WHERE:       Davos, Switzerland

    WHO:         Mr. Donald McCaffrey, President & CEO Resverlogix Corp.

    WHEN:        January 24 - 27, 2008

    As Canada's only WEF Technology Pioneer Award winner, Mr. McCaffrey who
is representing Resverlogix Corp. at the Annual World Economic Forum in
Switzerland is available for comments or interviews while at Davos.
Resverlogix was selected for the award because it is developing exceptionally
promising new molecules that increase the production of ApoA-l and high
density lipoprotein (HDL) for the treatment of atherosclerosis. According to
the World Health Organization, CVD is the number one cause of death globally,
an immense problem currently responsible for killing nearly 18 million people
annually worldwide.
    The Technology Pioneers 2008 were nominated by the world's leading
venture capital and technology companies. The final selection from
273 nominees was made by a panel of leading technology experts appointed by
the World Economic Forum. The award winners are companies that have been
identified as developing and applying highly transformational and innovative
technologies in the areas of energy, biotechnology and health, and information
    Only one of the Technology Pioneers 2008 is based in Canada while
23 companies are US-based. Israel and Switzerland each boast three; the United
Kingdom and Sweden two each; and France, Germany, India, the Netherlands and
Russia, one each. Technology Pioneers are nominated in three main categories:
Biotechnology/Health, Energy/Environment, and Information Technology.
    The entire list of Technology Pioneers and interviews with the CEOs of
the selected companies can be found here:

    About Cardiovascular Disease (CVD)

    CVD remains the number one killer of developed nations. Apolipoprotein
A-I (ApoA-I), the main component of high-density lipoprotein (HDL), is the
body's natural defense system against atherosclerosis (commonly referred to as
clogged arteries). In multiple human and animal studies over-expression or
repeated infusion of ApoA-I inhibit progression and induce regression of
atherosclerosis in animals and humans.

For further information:

For further information: Theresa Kennedy, VP, Corporate Communications
of Resverlogix Corp., Office phone: (604) 538-7072, Email:, Website:

Organization Profile

Resverlogix Corp.

More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890